Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics to Present at the Therapeutic Area Partnerships Meeting
Company Chosen as "Top Projects to Watch" in the Anti-Inflammatory/Autoimmune Industry
View HTML
Toggle Summary Aldeyra Therapeutics Reports Third Quarter and Year to Date 2014 Financial Results
LEXINGTON, Mass. , Nov. 10, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the third quarter and nine months ended
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
BURLINGTON, Mass. , Nov. 3, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the third quarter and the
View HTML
Toggle Summary Aldeyra Therapeutics to Present at Upcoming Investor Conferences
BURLINGTON, Mass., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will
View HTML
Toggle Summary Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials
BURLINGTON, Mass., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the expansion of its drug development team with three strategic hires
View HTML
Toggle Summary Aldeyra Therapeutics Reports Second Quarter 2014 Financial Results
BURLINGTON, Mass. , Aug. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, today announced its financial results for the second quarter ended June
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
BURLINGTON, Mass., July 23, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, today announced that it will issue its financial results for the second
View HTML
Toggle Summary Aldeyra Therapeutics to Join Russell Microcap Index
BURLINGTON, Mass., June 26, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, announced today that it will be added to the Russell Microcap Index when Russell
View HTML
Toggle Summary Aldeyra Therapeutics Appoints Stephen Tulipano Chief Financial Officer
BURLINGTON, Mass. , June 19, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Stephen Tulipano has joined Aldeyra as its Chief Financial
View HTML
Toggle Summary Aldeyra Therapeutics Reports First Quarter 2014 Financial Results
BURLINGTON, Mass. , June 11, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the first quarter ended March 31, 2014 .
View HTML